AZ, Oxford COVID-19 vax enters phase 2/3 trial

May 22, 2020

Oxford University and AstraZeneca are recruiting around 10,000 adults and children for a Phase 2/3 clinical trial of the experimental coronavirus vaccine, AZD1222.

An initial trial of the vaccine that was developed by the University of Oxford and licensed to AstraZeneca started on April 23 has already seen more than 1,000 volunteers aged 18-55 receive the injection. The next phases will add people aged 56 and older as well as children of 5 to 12 years.

The volunteers will be recruited across the U.K. and will record their reactions in an e-diary and attend some follow-up visits.

Yesterday, the U.S. secured almost a third of the first 1 billion doses planned for the COVID-19 vaccine by pledging up to $1.2 billion.

Read the press release